In the phase 2/3 trial, 437 study participants had “well-tolerated” reactions to the booster candidate, mRNA-1273.214, according to a June 8 news release.
At a 97.5 percent confidence level, the treatment “increased neutralizing geometric mean titers against omicron approximately eightfold above baseline levels.” The 50-microgram booster also had statistically significant results combating other variants of concern, including alpha, beta, gamma and delta, the release said.
Moderna CEO Stéphane Bancel said the company plans to have the booster candidate approved and distributed by late summer.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.